eTable 2. Response rates and survival of patients after attainment of secondary resectability under combination therapy^*1.

Reference	N	Chemotherapy regime	Response rate (%)	R0 resection rate (%)	Long-term survival after resection	EBM grade
Falcone 2007*2 (e3)	244	FOLFIRI vs. FOLFOXIRI	34 vs. 60 (p<0.0001)	6 vs. 15 (p=0.033)	––	Ib
Van Cutsem 2007/8 (e4), CRYSTAL*3	1198	FOLFIRI vs. FOLFIRI + cetuximab	38.7 vs. 46.9 (p=0.0038)	1.5 vs. 4.3 (p=0.0034)	––	Ib
Saltz 2008*4 (e5)	1401	XELOX/FOLFOX 4 + beva vs. XELOX/FOLFOX 4 + placebo	38 vs. 38 (p=0.99)	N/A	21.3 vs. 19.9 months (p=0.077)	IV

^*1 modified from (3);^*2 Resection rate as a secondary endpoint, FOLFOXIRI by continuous infusion; ^*3 Resection rate as a secondary endpoint, benefit only from the treatment of patients with k-ras wildtype tumors; ^*4 Resection rates as the result of exploratory subgroup analyses; EBM, evidence-based medicine; N/A, not available